Anaphylactoid-like reactions in a patient with hyperLp(a)lipidemia undergoing LDL apheresis with dextran sulfate adsorption and herbal therapy with the spice turmeric

Journal of Clinical Apheresis

Volumn 25, Issue 6, 2010, Pages 354-357

  Adamski, Jill ^a   Jamensky, Lita ^a   Ross, Joyce ^a   Siegel, Don L ^a   Sachais, Bruce S ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

alternative medicine; LDL apheresis; Lp(a); tumeric

Indexed keywords

ADSORBENT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; TURMERIC;

ADULT; ANAPHYLAXIS; APHERESIS; ARTICLE; CASE REPORT; HERBAL MEDICINE; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; MALE; MEMBRANE FILTER; SUPPLEMENTATION; TREATMENT OUTCOME;

ADSORPTION; ANAPHYLAXIS; BLOOD COMPONENT REMOVAL; CURCUMA; DEXTRAN SULFATE; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PHYTOTHERAPY;

EID: 78650152252     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20254     Document Type: Article

References (20)

1. Ariyo AA, Thach C, Tracy R, Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003; 349: 2108-2115.
2. Price JF, Lee AJ, Rumley A, Lowe GD, Fowkes FG,. Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh Artery Study. Atherosclerosis 2001; 157: 241-249.
3. Parker TS,. Dextran-sulfate cellulose adsorption for lowering Lp[a]. Chem Phys Lipids 1994; 67-68: 331-338.
4. Stefanutti C, Vivenzio A, Di Giacomo S, Mazzarella B, Ferraro PM, Abbolito S,. Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care. Transfus Apher Sci 2010; 42: 21-26.
5. Krieter DH, Steinke J, Kerkhoff M, Fink E, Lemke HD, Zingler C, Muller GA, et al. Contact activation in low-density lipoprotein apheresis systems. Artif Organs 2005; 29: 47-52.
6. Owen HG, Brecher ME,. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion 1994; 34: 891-894.
7. Lobo R, Prabhu KS, Shirwaikar A, Shirwaikar A,. Curcuma zedoaria Rosc. (white turmeric): a review of its chemical, pharmacological and ethnomedicinal properties. J Pharm Pharmacol 2009; 61: 13-21.
8. Koschinsky ML,. Novel insights into Lp(a) physiology and pathogenicity: more questions than answers? Cardiovasc Hematol Disord Drug Targets 2006; 6: 267-278.
9. Kostner KM, Kostner GM,. Therapy of hyper-Lp(a). Handb Exp Pharmacol 2005;(170): 519-536.
10. Klingel R, Mausfeld P, Fassbender C, Goehlen B,. Lipidfiltration-safe and effective methodology to perform lipid-apheresis. Transfus Apher Sci 2004; 30: 245-254.
11. Sachais BS, Katz J, Ross J, Rader DJ,. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia. J Clin Apher 2005; 20: 252-255.
12. Kroon AA, Mol MJ, Stalenhoef AF,. ACE inhibitors and LDL-apheresis with dextran sulphate adsorption. Lancet 1992; 340: 1476.
13. Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, Capila I, Lansing JC, Guglieri S, Fraser B, Al-Hakim A, Gunay NS, Zhang Z, Robinson L, Buhse L, Nasr M, Woodcock J, Langer R, Venkataraman G, Linhardt RJ, Casu B, Torri G, Sasisekharan R,. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008; 26: 669-675. (Pubitemid 351824692)
14. Kuo ML, Huang TS, Lin JK,. Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Biochim Biophys Acta 1996; 1317: 95-100.
15. Holt PR, Katz S, Kirshoff R,. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005; 50: 2191-2193.
16. Ramirez-Tortosa MC, Mesa MD, Aguilera MC, Quiles JL, Barõ L, Ramirez-Tortosa CL, Martinez-Victoria E, Gil A,. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis 1999; 147: 371-378.
17. Wilson B, Abraham G, Manju VS, Mathew M, Vimala B, Sundaresan S, Nambisan B,. Antimicrobial activity of Curcuma zedoaria and Curcuma malabarica tubers. J Ethnopharmacol 2005; 99: 147-151.
18. Adaramoye OA, Anjos RM, Almeida MM, Veras RC, Silvia DF, Oliveira FA, Cavalcante KV, Araújo IG, Oliveira AP, Medeiros IA,. Hypotensive and endothelium-independent vasorelaxant effects of methanolic extract from Curcuma longa L. in rats. J Ethnopharmacol 2009; 124: 457-462 [Epub May 27, 2009].
19. Enyeart JA, Liu H, Enyeart JJ,. Curcumin inhibits ACTH- and angiotensin II-stimulated cortisol secretion and Ca(v)3.2 current. J Nat Prod 2009; 72: 1533-1537.
20. Charles RE, Ponrasu T, Sivakumar R, Divakar S,. Angiotensin-converting enzyme inhibitory and antioxidant activities of enzymatically synthesized phenolic and vitamin glycosides. Biotechnol Appl Biochem 2009; 52: 177-184.